Protected: Tecartus^® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for the treatment of relapsed or refractory mantle cell lymphoma (r/r MCL)

By ONA Editor December 22, 2023 No Comments

$Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for the treatment of relapsed or refractory mantle cell lymphoma (r/r MCL)$

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

This post is password protected. Enter the password to view comments.

About Author

Related Posts

Gene modification could improve cancer treatment’s success rate

No evidence that CAR T cell therapy causes secondary cancers

FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma